14523-53-6

Basic information

• Product Name: spiro[4.5]dec-6-en-8-one
• Synonyms: spiro[4.5]dec-6-en-8-one
• CAS NO: 14523-53-6
• Molecular Formula: C10H14O
• Molecular Weight: 150
• Mol File: 14523-53-6.mol

Chemical Properties

• Boiling Point: 260.7°Cat760mmHg
• Flash Point: 121°C
• Appearance: /
• Density: 1.02g/cm³
• Vapor Pressure: 0.012mmHg at 25°C
• Refractive Index: 1.513
• CAS DataBase Reference: spiro[4.5]dec-6-en-8-one(CAS DataBase Reference)
• NIST Chemistry Reference: spiro[4.5]dec-6-en-8-one(14523-53-6)
• EPA Substance Registry System: spiro[4.5]dec-6-en-8-one(14523-53-6)

Safety Data

• Hazardous Substances Data: 14523-53-6(Hazardous Substances Data)

Usage

Uses

Used in the Food Industry:
Spiro[4.5]dec-6-en-8-one is used as a flavoring agent for its sweet smell, enhancing the taste and aroma of various food products.
Used in the Perfume Industry:
Decalone is utilized in the manufacture of perfumes, where its pleasant scent contributes to the creation of fragrances.
Used as a Chemical Intermediate:
In the chemical industry, spiro[4.5]dec-6-en-8-one serves as a chemical intermediate in the production of other organic compounds, facilitating the synthesis of a range of products.
Used in Scientific Research:
Spiro[4.5]dec-6-en-8-one has been identified as a potential component in the essential oils of various plant species and is studied for its potential medicinal and biological properties, including antibacterial and antifungal activities, indicating its use in research for new pharmaceutical applications.

InChI:InChI=1/C10H14O/c11-9-3-7-10(8-4-9)5-1-2-6-10/h3,7H,1-2,4-6,8H2

Upstream product

• 697-28-9 spiro[4.5]dec-6-ene 
• 82555-22-4 C₁₃H₂₂O₂ 
• 4134-23-0 1-cyclopentylidenemethyl-pyrrolidine 
• 78-94-4 methyl vinyl ketone 
• 10381-61-0 spiro[4.5]decan-6-ol 
• 13388-94-8 spiro[4.5]decan-6-one 
• 1528-30-9 methylenecyclopentane 
• 872-53-7 cyclopentanealdehyde 
• 30834-41-4 (Butanon-3')-yl-1-cyclopentan-carboxaldehyd 

Downstream Products

• 4027-35-4 spiro[4.5]decan-8-one 
• 859219-41-3 4,4,5,5-tetramethyl-2-(spiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane 
• 1516885-77-0 (S)-N-(3-(2-ethyl-4-(5-(3-ethyl-6,7-dihydro-4H-spiro[benzo[c]thiophene-5,1'-cyclopentan]-1-yl)-1,2,4-oxadiazol-3-yl)-6-methylphenoxy)-2-hydroxypropyl)-2-hydroxyacetamide 
• 1516885-70-3 (S)-3-(4-(2,3-dihydroxypropoxy)-3,5-dimethylphenyl)-1-(3-ethyl-6,7-dihydro-4H-spiro[benzo[c]thiophene-5,1'-cyclopentan]-1-yl)propan-1-one 

Relevant articles and documents

Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2

Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in the viral membrane. It has been the drug target of antiviral drugs such as amantadine and rimantadine. However, most of the current virulent influenza A viruses carry drug-resistant mutations alongside the drug binding site, such as S31N, V27A, and L26F, etc., each of which might be dominant in a given flu season. Among these mutations, the V27A mutation was prevalent among transmissible viruses under drug selection pressure. Until now, V27A has not been successfully targeted by small molecule inhibitors, despite years of extensive medicinal chemistry research efforts and high throughput screening. Guided by molecular dynamics (MD) simulation of drug binding and the influence of drug binding on the dynamics of A/M2 from earlier experimental studies, we designed a series of potent spirane amine inhibitors targeting not only WT, but also both A/M2-27A and L26F mutants with IC50s similar to that seen for amantadine's inhibition of the WT channel. The potencies of these inhibitors were further demonstrated in experimental binding and plaque reduction assays. These results demonstrate the power of MD simulations to probe the mechanism of drug binding as well as the ability to guide design of inhibitors of targets that had previously appeared to be undruggable.

CARBOXAMIDE DERIVATIVES

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Free-radical carbo-oximation of olefins and subsequent radical-ionic cascades

A sequential carbo-formylation cascade has been developed, involving a free-radical carbo-oximation process, followed by the hydrolysis of the oxime ether. For this purpose, we designed a new SEM O-protected sulfonyl oxime, which enable both rapid radical addition and hydrolysis under mild conditions. The resulting aldehyde-esters were then engaged in various nucleophilic cascades, such as Sakurai allylations or domino-Mukaiyama aldol condensation/ lactonizations. Addition of an amine and TMSCN similarly led after Strecker reaction/lactamization to α-cyano-piperidinones in good overall yield. Finally, a Pictet-Spengler/lactamization sequence was devised, which open a new entry toward the tricyclic core of eburnan alkaloids.

Inhibitors Of The Influenza A Virus M2 Proton Channel

Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.

ACID-LABILE ESTER MONOMER HAVING SPIROCYCLIC STRUCTURE, POLYMER, RESIST COMPOSITION, AND PATTERNING PROCESS

An acid-labile ester monomer of spirocyclic structure has formula (1) wherein Z is a monovalent group having a polymerizable double bond, X is a divalent group which forms a cyclopentane, cyclohexane or norbornane ring, R2 is H or monovalent hydrocarbon, R3 and R4 are H or monovalent hydrocarbon, or R3 and R4, taken together, stand for a divalent group which forms a cyclopentane or cyclohexane ring, and n is 1 or 2. A polymer obtained from the acid-labile ester monomer has so high reactivity in acid-catalyzed elimination reaction that the polymer may be used to formulate a resist composition having high resolution.

HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS

The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.